NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
Key Highlights
- ➤NEO100 six-month progression-free survival reached 48.9%, versus 20% historical benchmark
- ➤NEO100 median overall survival was 26.1 months in 24-patient efficacy population
- ➤FDA Type B meeting scheduled January 2027 for NEO100 accelerated approval and Phase 3
- ➤NEO212 Phase 1 dose escalation completed with no observed myelosuppression
- ➤FDA Type B meeting scheduled November 23 for NEO212 Phase 2 design discussions
Expert Statements
Thomas C. Chen, Chief Medical Officer of NeOnc Technologies Holdings
“Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma”
DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia. The presentations put the company's intranasal NEO100 and oral NEO212 programs in focus, with additional clinical evidence arriving as NeOnc prepares for important FDA discussions and continues to attract substantial insider buying.
The first presentation, abstract CTNI-26, titled Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, provides updated Phase 1/2a and compassionate-use experience. Presented by Chief Medical Officer Thomas C. Chen, MD, PhD, the findings are particularly important because they build on previously reported survival and progression-free survival results in a difficult-to-treat patient population.
Get started
Create a free account to read the full story.